GE HealthCare reports second quarter 2026 financial results
GE HealthCare reported Q2 2026 revenue of $5.3 billion, up 5.7% year-over-year, with organic growth of 3.5% driven by strength in Pharmaceutical Diagnostics and Advanced Imaging Solutions. The company posted record organic orders growth of 11.1% and a book-to-bill ratio of 1.15 times, growing its backlog to $23.9 billion while reaffirming full-year guidance.
Key figures
- Eps
- 1.24
- Revenue
- $5.3 billion
- Guidance
- Full-year 2026 organic revenue growth 3.0% to 4.0%; Adjusted EBIT margin 15.4% to 15.7%; Adjusted EPS $4.80 to $5.00; Free cash flow approximately $1.6 billion
- Revenue Yoy
- 5.7%
- Backlog
- $23.9 billion
- Adjusted eps
- 1.13
- Book to bill
- 1.15 times
- Adjusted ebit
- $750 million
- Buyback spend
- $200 million
- Orders growth
- 11.1%
- Free cash flow
- $68 million
- Shares repurchased
- 3300000
- Operating cash flow
- $168 million
- Adjusted ebit margin
- 14.2%
- Organic revenue growth
- 3.5%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.